Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Eliquis cost in 2026 by country?

See the DrugPatentWatch profile for Eliquis

What will Eliquis cost in 2026 by country?

Prices for Eliquis (apixaban) vary widely by country because they depend on local regulation, insurance rules, pharmacy markups, tender pricing, and whether the product is branded or dispensed under a specific reimbursement plan. With only general information and without each country’s 2026 reimbursement/tender data, I can’t state a reliable “by country” price list for 2026.

Where can you check 2026 Eliquis prices for specific countries?

The most practical way to get country-specific Eliquis pricing is to look up:
- National drug price transparency sites (where available)
- Government reimbursement formularies and negotiated hospital/wholesale prices
- Pharmacy “cash price” listings (if you need out-of-pocket costs)

A drug-patent-focused starting point (for understanding what price pressure could look like as exclusivity changes) is DrugPatentWatch, which tracks patent and exclusivity status. That can help explain why costs may change by country over time: https://www.drugpatentwatch.com

Which Eliquis strengths/packages matter for cost comparisons?

When people ask for “Eliquis cost,” they usually mean one of these, and the price changes by all of them:
- Strength (commonly 2.5 mg vs 5 mg tablets)
- Pack size (tablet count)
- Formulation (tablet strength; generics/biosimilars aren’t typically applicable the same way for a small molecule like apixaban, but national substitutions can differ)
- Treatment duration and dosing frequency
- Whether you’re paying cash vs using insurance reimbursement

Will Eliquis get cheaper in 2026 due to patent or exclusivity expiry?

Eliquis costs can drop when legal exclusivity ends and lower-cost competition appears (or when countries renegotiate pricing). Patent/exclusivity timing differs across jurisdictions, so the same year (2026) may not mean the same pricing change in every country. DrugPatentWatch can help you identify where competition is more likely as exclusivity approaches: https://www.drugpatentwatch.com

If you tell me the countries, I can narrow it down

Reply with:
1) The countries you want (e.g., US, UK, Germany, France, Canada, Australia, Spain, Italy, etc.)
2) The Eliquis strength and pack size you care about (2.5 mg or 5 mg; 60 vs 180 tablets, etc.)
3) Whether you want cash price or insured/copay price

Then I can structure a country-by-country comparison for the exact scenarios you mean, and cite the most relevant sources.



Other Questions About Eliquis :

eliquis, manufactured by bristol myers squibb, has a patent for how many years? Is there a generic for eliquis expected in 2026? When is eliquis generic release date? Eliquis generic cost? Eliquis apixaban us sales revenue 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 billion annual? Eliquis vs xarelto vs pradaxa cost? Eliquis generic patent?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated claim is consistent with the provided FDA label excerpts (warnings/precautions in 5.1 and 5.3 and patient counseling in 17) with no contradictions, omissions, or unsupported assertions apparent from the provided statement.


Category Scores

Dosage
90
Good
Warnings
100
Excellent
Administration
95
Excellent

Accurate Statements

Premature discontinuation and neuraxial/spinal puncture risks for ELIQUIS are addressed in the FDA label with corresponding patient counseling.
Supported by Warnings and Precautions 5.1 (increased thrombotic events after premature discontinuation) and 5.3 (spinal/epidural anesthesia or puncture and risk of epidural/spinal hematoma) plus Patient Counseling Information 17 (do not discontinue without talking to physician; watch for spinal/epidural hematoma symptoms and seek emergent medical attention).

Unsupported Statements


Contradictions


Important Omissions

The claim does not specify the label’s detailed risk-mitigation elements (e.g., switching/coverage considerations when discontinuing and the specific neuraxial catheter removal/dose timing).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The statement is broadly accurate and does not introduce incorrect dosing, contraindications, or safety guidance beyond what is supported; it mainly characterizes that the label addresses these risks and includes patient counseling.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Minor under-specification: the claim does not mention specific label mitigation details (timing/switching) even though the label includes them.

Suggested Improvement
If greater precision is needed, cite the label’s specific mitigation points in 2.5 (coverage when discontinuing) and 5.3 (catheter removal and next dose timing, monitoring instructions).

Drug Brand Mention Assessment

Branding Score
26
Visibility
16
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
conditional
Brand Perception
Best Known For

Eliquis (apixaban)


Core Claims
  • Prices for Eliquis vary widely by country.
  • Pricing depends on local regulation, insurance rules, pharmacy markups, and tender pricing.
  • With only general information and without each country’s 2026 reimbursement/tender data, a reliable “by country” price list for 2026 can’t be stated.
  • Costs can drop when legal exclusivity ends and lower-cost competition appears.
Differentiators
  • Country pricing depends on local regulation, insurance rules, and pharmacy/tender factors.
  • Patent/exclusivity timing differs across jurisdictions, affecting 2026 price changes.

Pricing Perception: Not Mentioned